Interleukin-6 inhibition

Interleukin-6 inhibition has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Sep 15, 2026: “Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on interleukin-6 inhibition

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country

What did studies of interleukin-6 inhibition find?

1

Studies of interleukin-6 inhibition measured one outcome, neutrophil-to-lymphocyte ratio.

Neutrophil-to-lymphocyte ratio

downin humans1

1 study
  1. Interleukin-6 inhibition decreases neutrophil-to-lymphocyte ratio in humans (established cardiovascular disease or elevated cardiovascular risk).

    “Direct interleukin-6 (IL-6) inhibition produced the clearest dose-dependent reduction in NLR”

    Reviewestablished cardiovascular disease or elevated cardiovascular risk

    Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker

    Cureus

More on Neutrophil-to-lymphocyte ratio

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 0Nov 2026: 01 paper in 12 months